IVF NewsNews: Microembart2.0 Conference
Dr. Ved Prakash 19 April 2025
 
News: Lifeinvitro Academy’s upcoming certificate courses in ART
Lifeinvitro Academy 12 April 2025
The Center for Healthcare Entrepreneurship (CfHE), IIT Hyderabad, in collaboration with STECH IVF Solutions and ZY-QUEST Global, is pleased to announce three specialized certificate courses in the domain of Assisted Reproductive Technologies. [ Full Article ]
News: Insights from the HFEA’s 2024 National Patient Survey: Satisfaction, Disparities, and the Prevalence of Add-On Treatments
IVF.net NewsDesk 08 April 2025
An Examination of Patient Experiences and the Need for Enhanced Communication in UK Fertility ServicesThe Human Fertilisation and Embryology Authority (HFEA) recently released its 2024 National Patient Survey, offering a comprehensive overview of patient experiences within the UK’s fertility treatment landscape. The survey, encompassing responses from 1,500 individuals, reveals that 73% of fertility patients expressed satisfaction with their most recent treatment. This marks the third consecutive survey where satisfaction levels have exceeded 70%, indicating a consistent trend over the past decade. Notably, patients in the North East of England reported the highest satisfaction rates at 86%, while those in Wales reported the lowest at 68%. Despite these positive overall figures, the survey highlights significant disparities among different demographic groups. Satisfaction levels among Asian and Black patients were notably lower, at 50% and 59% respectively. These groups also reported less satisfaction with the quality of information provided by clinics, with 66% of Asian and Black patients expressing contentment, compared to 78% overall. The HFEA suggests that these disparities may be linked to lower birth rates and reduced access to NHS-funded treatments within these communities. The survey also sheds light on the concerning prevalence of unproven add-on treatments in fertility care. Approximately 73% of patients reported using at least one additional test, treatment, or emerging technology during their fertility journey. Commonly utilized add-ons include acupuncture, supplements, and additional medications, many of which lack substantial evidence supporting their efficacy in enhancing fertility outcomes. These extras can be costly, with some treatments reaching up to £1,500. Alarmingly, only 52% of patients had the effectiveness of these add-ons explained to them, and a mere 37% were informed about potential risks. Julia Chain, Chair of the HFEA, expressed concern over these findings, emphasizing the need for clinics to provide clear and comprehensive information about the efficacy, costs, and risks associated with additional treatments. The HFEA’s Code of Practice mandates that clinics must offer patients a transparent understanding of any treatment add-on, including its likelihood of increasing the chance of a successful pregnancy. Despite ongoing efforts since 2017 to reduce the use of unproven extras, their prevalence remains high, underscoring the necessity for improved communication and patient education. The survey further revealed that NHS-funded patients are experiencing longer wait times before commencing treatment. Only 35% of these patients began treatment within a year of consulting their GP, compared to 53% of self-funded patients. This disparity highlights ongoing challenges in the provision of timely fertility care within the NHS framework. In response to these insights, the HFEA aims to address these disparities and enhance patient experiences by advocating for equitable access to fertility treatments, ensuring transparent communication regarding treatment options, and promoting the provision of evidence-based care. The findings from the 2024 National Patient Survey serve as a crucial tool in informing policy and guiding improvements within the UK’s fertility services. Sources: 26 March 2025. HFEA 26 March 2025. HFEA 26 March 2025. BBC News [ Full Article ]
News: Sweeping Layoffs at U.S. Health Agencies Jeopardize Infertility Research and Public Health Programs
IVF.net NewsDesk 08 April 2025
In a significant move, the U.S. Department of Health and Human Services (HHS) has initiated extensive layoffs, leading to the elimination of approximately 10,000 positions across various health agencies, including the Centers for Disease Control and Prevention (CDC). This decision has particularly impacted the CDC’s team dedicated to infertility research and assisted reproductive technologies, effectively disbanding the group responsible for tracking in vitro fertilization (IVF) cycles and maintaining related databases. The disbandment of this specialized team has raised alarms among reproductive health advocates and medical professionals. Barbara Collura, president and CEO of the national infertility group RESOLVE, expressed concern over the absence of experts to inform public policy, brief Congress, and advance public awareness on infertility causes and treatments. The sudden loss of such expertise poses challenges for ongoing and future initiatives aimed at addressing infertility, a condition affecting one in six individuals worldwide. These layoffs are part of a broader reorganization plan within HHS, which aims to reduce the department’s workforce by approximately 20,000 employees. The restructuring includes merging several agencies into a new entity, the Administration for a Healthy America, and reorienting the CDC’s focus toward infectious disease programs. Critics argue that such significant cuts will severely impact the department’s capacity to respond to public health crises and maintain essential services. The implementation of these layoffs has been marked by confusion and lack of transparency. Many employees reportedly discovered their termination only when their entry badges failed to grant access to their workplaces. Long lines formed at federal building entrances due to increased security measures, and senior leaders were reassigned to distant locations, prompting some to leave voluntarily. This chaotic process has left many professionals feeling betrayed and uncertain about their futures. Beyond infertility research, other critical public health programs have been affected. For instance, the National Institute for Occupational Safety and Health (NIOSH) faced significant layoffs, particularly impacting its mining safety research and respirator approval programs. The closure of NIOSH’s laboratory in Spokane, Washington, and the cessation of the National Firefighter Registry for Cancer are among the notable consequences. Such reductions raise concerns about the nation’s ability to address occupational health and safety effectively. Public health experts, former officials, labor unions, and lawmakers have voiced strong opposition to these cuts. Senator Patty Murray described the plan as “an absurd suggestion” that “defies common sense,” especially amid ongoing health challenges such as outbreaks of bird flu, measles, and the fentanyl epidemic. Labor unions have also pledged to contest the layoffs, emphasizing the detrimental impact on the nation’s public health infrastructure. The dismantling of the CDC’s infertility research team and other public health programs underscores the far-reaching implications of these workforce reductions. As the nation grapples with complex health issues, the loss of specialized expertise and resources may hinder efforts to advance medical research, implement effective public health strategies, and provide essential services to vulnerable populations. Sources: 2 April 2025. NBC News 3 April 2025. Forbes 2 April 2025. The Guardian 2 April 2025. The New Republic [ Full Article ]
News: Breaking New Ground: Restoring Fertility in Male Cancer Survivors
IVF.net NewsDesk 08 April 2025
Advancements in medical research have opened new avenues for addressing infertility in male survivors of childhood cancer. A groundbreaking case involves Jaiwen Hsu, who, at the age of 11, was diagnosed with osteosarcoma—a type of bone cancer. The chemotherapy regimen necessary to treat his cancer posed a significant risk to his future fertility. In response, doctors at the University of Pittsburgh Medical Center (UPMC) harvested and cryopreserved a sample of his testicular tissue, containing sperm-forming stem cells, before he commenced treatment. At 26, Hsu underwent a pioneering procedure where his preserved spermatogonial stem cells were reintroduced into his testes. This approach aims to regenerate spermatogenesis—the process of sperm production. While this technique has demonstrated success in animal models, including mice and monkeys, it remains experimental in humans. Early indications suggest that the transplanted tissue remains unharmed, though detectable sperm production has yet to be observed. The implications of this procedure are particularly significant for prepubescent boys undergoing treatments that may compromise fertility. Unlike post-pubertal males, who have the option of sperm banking, younger patients lack mature sperm for preservation. Testicular tissue cryopreservation offers a potential solution by storing tissue that contains immature sperm cells, which could later be matured or reimplanted to restore fertility. However, several challenges accompany this innovative approach. Ensuring the long-term viability and safety of cryopreserved testicular tissue is paramount. Risks include potential contamination with malignant cells, which could lead to cancer recurrence upon reimplantation. Additionally, the efficiency of spermatogenesis restoration and the overall success rates of such procedures in humans remain under investigation. Ethical considerations also play a crucial role in the application of this technology. The experimental nature of testicular tissue transplantation raises questions about consent, particularly when procedures are performed on minors. Furthermore, the accessibility and cost of such treatments may limit their availability, potentially leading to disparities in care. Despite these challenges, the progress in spermatogonial stem cell transplantation represents a promising frontier in oncofertility—a field dedicated to preserving reproductive health in cancer patients. Ongoing research and clinical trials are essential to refine these techniques, address safety concerns, and establish standardized protocols. As the medical community continues to explore these innovations, there is hope that fertility preservation will become an integral component of comprehensive cancer care for young patients. Sources: 26 March 2025. medRxiv 28 March 2025. The Independent 28 March 2025. Wired 2 April 2025. Cancer Health [ Full Article ]
News: ART & Embryology training program
Chennai Fertility Centre and Research Institute 01 April 2025
Training Batch Schedule May 2025 Batch - V : 12th to 26th MayThe International School of Embryology a unit of Chennai Fertility Centre and Research Institute was established to offer training in Advanced Reproductive Techniques and Embryology for clinicians and embryologists. It will help them to know in-depth knowledge and have good hands-on training. The members of our teaching faculty aim to bring Clinician and Embryologists to the highest level of knowledge about Assisted Reproductive Technology and practical capability. Our courses cover basics in Andrology, Embryology, ICSI & Cryosciences (Hands-on). Limited Seats. For admission Contact 9003111598 / 8428278218 [ Full Article ]
Webinar: Green IVF III: Taking Action!
International IVF Initiative 24 March 2025
3pm ET/ 7pm UK/ 8pm CET, Tuesday 25th Mar 2025 CHECK REGIONAL TIME Moderators: Dr. Mina Alikani and Dr. Jacques Cohen [ Full Article ]
News: Hong Kong Proposes Lifting 10-Year Storage Cap on Frozen Reproductive Materials
IVF.net NewsDesk 24 March 2025
The Hong Kong government has proposed removing the current 10-year storage limit for frozen sperm, eggs, and embryos, marking a major shift in the city’s reproductive health policy. The proposed change is part of broader amendments to the Human Reproductive Technology Ordinance (Cap. 561), reflecting societal shifts and the growing demand for fertility preservation services. As fertility challenges rise, particularly among women choosing to delay childbearing, the government aims to offer greater flexibility for individuals and couples planning their reproductive futures. The reform comes amid concerns over Hong Kong’s declining birth rate and aging population. With the city recording some of the world’s lowest fertility rates, officials are considering various ways to support those facing reproductive health challenges. By eliminating the arbitrary 10-year time limit, the government hopes to reduce unnecessary pressure on individuals who freeze their reproductive materials, whether for medical or social reasons. This would align Hong Kong more closely with international practices, where extended or unlimited storage periods are increasingly common. Under the current law, gametes and embryos must be discarded after a decade unless exceptional medical reasons are approved by the Council on Human Reproductive Technology. The proposed changes would remove this restriction, allowing individuals to store their reproductive materials for as long as they wish, provided they continue to meet regulatory requirements. The flexibility is particularly beneficial for cancer patients or those undergoing treatments that may impair fertility, giving them more control over family planning decisions in the long term. The legislative proposal also aligns with newly drafted principles for ethical and safe fertility care outlined by the Council on Human Reproductive Technology in its 2025 Code of Practice. These principles emphasize patient autonomy, transparency, and equitable access to services. The updated guidelines will continue to ensure safety and accountability for assisted reproductive technology providers, while recognizing advances in medical science and changing societal expectations. The public consultation on the proposal is now open, with the government inviting feedback from healthcare professionals, patients, and the general public. If approved, the amendments will modernize Hong Kong’s regulatory framework, offer greater reproductive autonomy, and potentially contribute to reversing the city’s fertility decline by making it easier for residents to plan parenthood on their own terms. Sources 13 March 2025. The Standard 13 March 2025. Council on Human Reproductive Technology 13 March 2025. The Council on Human Reproductive Technology 14 March 2025. The Hong Kong Free Press [ Full Article ]
News: Semen Quality as a Predictor of Male Longevity: Insights from a Comprehensive Danish Cohort Study
IVF.net NewsDesk 10 March 2025
Recent research has unveiled a compelling association between semen quality and male longevity. A comprehensive study conducted by Copenhagen University Hospital analyzed data from 78,284 Danish men over a span of five decades, from 1965 to 2015. The findings indicate that men with higher total motile sperm counts (TMC) tend to live longer than those with lower counts. Specifically, the study revealed that men with a TMC exceeding 120 million had an average life expectancy of 80.3 years, whereas those with counts below 5 million had a life expectancy of 77.6 years. This suggests a difference of approximately 2.7 years between the highest and lowest semen quality groups. Importantly, this correlation persisted even after adjusting for variables such as educational level and pre-existing medical conditions in the decade preceding semen assessment. The underlying mechanisms connecting semen quality to overall health remain a subject of investigation. One hypothesis posits that semen quality may serve as a biomarker for general health status, reflecting the body’s physiological well-being. Factors such as oxidative stress, which can damage sperm DNA, might play a role in both reduced semen quality and increased susceptibility to age-related diseases. Notably, the study did not delve into specific causes of mortality among men with varying semen qualities. Future research aims to explore potential links between poor semen quality and particular health outcomes, such as cardiovascular diseases or cancers. Identifying these associations could lead to early interventions and personalized healthcare strategies for men identified with lower semen quality. These findings underscore the potential of semen analysis as a valuable tool beyond fertility assessments. Routine evaluation of semen quality in younger men could serve as an early indicator of future health risks, allowing for timely preventive measures. This approach aligns with the broader perspective that reproductive health is intricately linked to overall health, emphasizing the need for integrated medical evaluations. In conclusion, the observed association between higher semen quality and increased life expectancy highlights the importance of considering reproductive metrics in the context of general health assessments. As research progresses, a deeper understanding of the biological pathways connecting semen quality to longevity may emerge, offering novel insights into male health and aging. Sources:
4 March 2025. CNN 5 March 2025. The Guardian 5 March 2025. Sky News 5 March 2025. Independent 5 March 2025. ESHRE 5 March 2025. RiceMasonNoble 5 March 2025. Human Reproduction 5 March 2025. Human Reproduction [ Full Article ]
Announcement: Top Quality In IVF Lab
Dr. Keshav Malhotra 07 March 2025
|
